🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

SANOFI CONS HEALTHC IND L SANOFICONR NSEPHARMA

Healthcare · Drug Manufacturers - General · India
https://www.sanofi.com/en/india/consumer-healthcare
Company Profile ↓
₹4,201.70
-16.87% 1Y
Mkt Cap₹9,676.78 Cr
P/E40.30
P/B29.89
Div. Yield1.65%
52W High₹5,212.29
52W Low₹3,938.88
Book Value₹166.73
EPS (TTM)₹104.27

Company Overview

Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. The company offers products in the allergy, physical wellness, and pain care segments under Allegra, Combiflam, Avil, DePURA, Festal, and other brand names through distributors, wholesalers, government institutions and hospitals, pharmacy chains, and e-commerce platforms. The company was incorporated in 2023 and is based in Mumbai, India. Sanofi Consumer Healthcare India Limited operates as a subsidiary of Opella Healthcare Participations B.V.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 62.5%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 77.0%.

Consistent Profit Growth

Net profit has compounded at 20.7% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 27.0% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 40.3, below the sector median of 41.6.

Healthy Margins

Maintains a net profit margin of 27.4%.

Recent Developments

  • Dec 2025 Revenue of ₹878.00 Cr (+22.6% YoY); net profit ₹240.10 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +22.6%, earnings +32.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 27.0%, profit CAGR 20.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:27.01%
1 Year:22.59%

Compounded Profit Growth

5 Years:20.67%
1 Year:32.65%

Stock Price Performance

1 Year:-16.87%
6 Months:-3.26%
3 Months:-9.48%
1 Month:-7.32%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 21% of range
₹3,938.88 ₹5,212.29
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)36.31 · Neutral
Price Performance
1M-7.32%
3M-9.48%
6M-3.26%
1Y-16.87%
Valuation vs Sector

P/E of 40.30 is below the sector median of 41.64 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 62.5%.
  • Healthy ROCE of 77.0%.
  • Excellent profit margin of 27.4%.
  • Compounding revenue at 27.0% over 5 years.
  • Profit CAGR of 20.7% over 5 years.
  • Generates positive free cash flow.

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
40.30
Industry PE
41.64
Forward P/E
31.38
PEG Ratio
-
Book Value
₹166.73
Price to Book
29.89
P/S
10.96
EV/EBITDA
28.66
Dividend Yield
1.65%

Growth (CAGR)

Revenue 5Y
27.01%
Profit 5Y
20.67%
Revenue (YoY)
22.59%
Earnings (YoY)
32.65%

Profitability & Returns

ROCE
77.02%
ROE
62.53%
ROA
43.89%
Profit Margin
27.35%
Op Margin
33.87%
Gross Margin
68.13%
EPS (Latest Qtr)
₹29.87
EPS (TTM)
₹104.27

Balance Sheet & Liquidity

Debt/Equity
0.06
Quick Ratio
3.37
Current Ratio
3.85
Debt
₹24.80 Cr
Total Assets
₹706.40 Cr
Current Assets
₹663.40 Cr
Working Capital
₹365.90 Cr

Ownership

Promoter Holding
72.52%
Chg in Prom Hold
1.06%
FII / Inst Holding
19.59%
Chg in FII Hold
0.52%

Financial Snapshot

Enterprise Value
₹9,676.78 Cr
Total Revenue (TTM)
₹878.00 Cr
EBITDA
₹334.10 Cr
Free Cash Flow
₹167.20 Cr
Operating Cash Flow
₹174.80 Cr
Shares Outstanding
₹2.30 Cr
Gross Margin
68.13%
Payout Ratio
64.93%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SANOFICONR SANOFI CONS HEALTHC IND L NSEPHARMA 4,201.70 40.30 ₹9,676.78 Cr 1.65% 77.02% 62.53% 27.01% 20.67%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 172.60 Cr220.90 Cr233.90 Cr251.00 Cr229.20 Cr235.70 Cr
Cost of Revenue 38.80 Cr61.20 Cr61.80 Cr68.30 Cr56.20 Cr56.30 Cr
Gross Profit 133.80 Cr159.70 Cr172.10 Cr182.70 Cr173.00 Cr179.40 Cr
Operating Expenses 71.80 Cr92.50 Cr90.40 Cr96.30 Cr87.40 Cr93.40 Cr
Operating Income 62.00 Cr67.20 Cr81.70 Cr86.40 Cr85.60 Cr86.00 Cr
EBITDA 69.20 Cr82.40 Cr88.00 Cr94.40 Cr94.40 Cr95.60 Cr
Interest Expense 40.00 L50.00 L60.00 L50.00 L50.00 L40.00 L
Pretax Income 66.80 Cr78.90 Cr84.10 Cr90.50 Cr90.70 Cr91.90 Cr
Tax Provision 16.80 Cr18.20 Cr21.20 Cr24.00 Cr22.90 Cr23.10 Cr
Net Income 50.00 Cr60.70 Cr62.90 Cr66.50 Cr67.80 Cr68.80 Cr
Diluted EPS 21.6926.3627.3128.8729.4429.87

Profit & Loss (Annual)

Figures in INR.

Metric Dec 2023Dec 2024Dec 2025
Revenue 544.30 Cr716.20 Cr878.00 Cr
Cost of Revenue 194.00 Cr228.80 Cr279.80 Cr
Gross Profit 350.30 Cr487.40 Cr598.20 Cr
Operating Expenses 133.10 Cr221.20 Cr300.80 Cr
Operating Income 217.20 Cr266.20 Cr297.40 Cr
EBITDA 221.30 Cr255.30 Cr334.10 Cr
Interest Expense 20.00 L4.00 Cr2.10 Cr
Pretax Income 219.30 Cr246.80 Cr320.30 Cr
Tax Provision 54.40 Cr65.80 Cr80.20 Cr
Net Income 164.90 Cr181.00 Cr240.10 Cr
Diluted EPS 71.6078.59104.27

Balance Sheet (Annual)

Figures in INR.

Metric Dec 2023Dec 2024Dec 2025
Total Assets 345.40 Cr431.30 Cr547.00 Cr
Current Assets 335.20 Cr391.70 Cr494.30 Cr
Cash & Equivalents 1.60 Cr326.90 Cr374.80 Cr
Inventory 96.60 Cr40.90 Cr61.90 Cr
Receivables 31.60 Cr13.70 Cr29.60 Cr
Total Liabilities 137.80 Cr158.30 Cr163.00 Cr
Current Liabilities 129.90 Cr130.60 Cr128.40 Cr
Long Term Debt ---
Total Debt 020.30 Cr24.80 Cr
Total Equity 207.60 Cr273.00 Cr384.00 Cr
Shares Outstanding 2.30 Cr2.30 Cr2.30 Cr

Cash Flows (Annual)

Figures in INR.

Metric Dec 2023Dec 2024Dec 2025
Operating Cash Flow -40.00 L439.00 Cr174.80 Cr
Investing Cash Flow 01.90 Cr7.60 Cr
Financing Cash Flow 2.00 Cr-115.60 Cr-134.50 Cr
Capital Expenditure -4.00 Cr-9.90 Cr-7.60 Cr
Free Cash Flow -4.40 Cr429.10 Cr167.20 Cr
Net Change in Cash 1.60 Cr325.30 Cr47.90 Cr

Ratios (Annual)

Figures in %.

Metric Dec 2023Dec 2024Dec 2025
Gross Margin % 64.4%68.1%68.1%
Operating Margin % 39.9%37.2%33.9%
Net Margin % 30.3%25.3%27.3%
ROE % 79.4%66.3%62.5%
ROCE % 100.8%88.5%71.0%

Shareholding Pattern

Insiders
72.52%
Institutions
19.59%
Public Float
71.28%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SANOFICONR

Google News Mon, 15 Jun 2026

Is It Worth Considering Sanofi Consumer Healthcare India Limited (NSE:SANOFICONR) For Its Upcoming Dividend? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMihwJBVV95cUxQcjQyVngyQk82d01ILU0zR3Bad2RxQjhvRFROZWhTUkNlQ0ZNZjFNdmhMZUFpWHE4WkpYT3ZuOVZfdWY3Z05TRktoRkgxYzJmYWxkS1ZGMmtQMUY3YnBrSnV3TWpjVXdwanN6U1BuVjRvWnVsU2Y0Q0xsWWNRcFNDSzBsNTVwZVY2bjduRH…

Google News Fri, 14 Nov 2025

SANOFICONR Stock Price and Chart — NSE:SANOFICONR - TradingView

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTFBYWmprVy1YTmVRTzNlTXp5WU5qRmx6VU0zSGFHeEppVmx3aUdYUDhSVTFMSTlpaG41WFdtMkNwdmRRS3cxQnA5dkJrVUV5VHhLTXpjaGNVNHU0dHhIbkFQMA?oc=5" target="_blank">SANOFICONR Stock Price and Chart — NS…

Google News Wed, 26 Aug 2026

Sanofi (SANOFICONR.NS) Financial Update: The Report Provides a New Financial Snapshot at the Close; Investor Response: Shares Finish 0.43% Down for the Current Session - GAAP Earnings Report - siam.in

<a href="https://news.google.com/rss/articles/CBMiqwJBVV95cUxPczFPQ0xSSkZqbV9oYUZjdi1fZnZYM28tdTVXOFRkX3gxeTgwVENHQkxFTm1kUVBMaUJkTFBGNHNzTTRTOUg2eEhqOGtJOHlkRzFjS1JWZm92cnduaG9md2dDSnFWaUcwamNvMFJNVlFxZFpaY01JYjVfaHV2a1RsbTRrd1Vtd0ZYd1QxU3…

Google News Wed, 24 Jun 2026

SANOFICONR Q1 2026 Earnings: Strong Revenue Surge of 22.6% Despite Marginal Stock Dip - New Analyst Coverage - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOR0d1ZGQxZWlaYng2NHp0ZE9YUXJWcXJTaVB5ald4RWtMMmhsUE0zT0ZXd3p3R3pGaDdvbmdQcDI1NjR3T21KMGVkSzlpRm5sYUpuOUREbm9vZkdZRnVfV1hvSVp6RkY1YVdNLWFqcm9ERU9PUnVoUGNLckhNQklOMlV3YlEyTUo1bkVUX2…

Google News Fri, 26 Jun 2026

Sanofi Consumer Healthcare India Share Price Target 2026: Rs 5,500 Analyst Forecast - Univest

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxQVW5kZ0hZekluQ28tUGswSnF6aDgzZGRBSVZfR0c2c1B5bFBwX1NmUGJuVjJpRVA5TzVaUUhQRkkxUWhkRjJKblNxM3lvWVZpbVNHWUNoNzRyaUxZN0JGU2RHMnVzbUl5ckxUOXI3c2NIQWdVR2lsUHlKNGVJZTNvLXltbDJFRFJy?oc=5"…

Google News Fri, 21 Nov 2025

These 4 Measures Indicate That Sanofi Consumer Healthcare India (NSE:SANOFICONR) Is Using Debt Safely - simplywall.st

<a href="https://news.google.com/rss/articles/CBMihwJBVV95cUxNTEROWjExdDhxdUp2eE80WFBNTHMwOGVhSlVha1NaNDFrajM2c00xanJrUVE5czlzbU02bWdwdUUtMXFxc3c5U0tPWDhDUHlOeHNuWmlqa040XzZtUWJOVjNyZXRkOTVhVEJzWTR6ZTd3cHJEOHlRY0tRMlhqYVFBdTdobFV0ZlF6ZWJ5V2…

SANOFICONR — Frequently Asked Questions

What is the current share price of SANOFI CONS HEALTHC IND L (SANOFICONR)?

As of 2026-09-08 04:53 IST, SANOFI CONS HEALTHC IND L (SANOFICONR) trades at ₹4,201.70 on NSE. Its 52-week range is ₹3,938.88 to ₹5,212.29.

What is the market capitalisation of SANOFICONR?

SANOFI CONS HEALTHC IND L (SANOFICONR) has a market capitalisation of ₹9,676.78 Cr on NSE.

What is the P/E ratio of SANOFICONR?

SANOFICONR trades at a trailing price-to-earnings (P/E) ratio of 40.30. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 29.89.

Does SANOFICONR pay a dividend?

SANOFI CONS HEALTHC IND L (SANOFICONR) currently offers a dividend yield of 1.65%.

What is the return on equity (ROE) of SANOFICONR?

SANOFICONR has a return on equity (ROE) of 62.53%. Its return on capital employed (ROCE) is 77.02%.

Is SANOFICONR a good stock to buy?

This page provides a data-driven analysis of SANOFI CONS HEALTHC IND L (SANOFICONR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space